date,open,high,low,close,volume,title,description,title_sentiment,desc_sentiment,daily_change_pct,market_sentiment,next_day_change_pct,next_day_sentiment
2018-02-09 13:02:27.548,897.95,910.0,870.0,904.95,46879.0,"Competitive pricing leads to higher volume growth, says Dr Lal Pathlabs","Dr Lal Pathlabs' revenue growth was aided by a low base in Q3 while volume growth momentum continues. The street is a bit concerned about pricing pressure in an industry that has become so competitive now. In an interview to CNBC-TV18, Om Manchanda, CEO of Dr Lal Pathlabs discussed the company's Q3 performance.",positive,positive,0.7795534272509606,neutral,-0.021973192704905,neutral
2018-02-09 18:01:12.323,897.95,910.0,870.0,904.95,46879.0,CLSA maintains 'buy' on Dr Lal PathLabs,Dr Lal PathLabs' volume growth in the past two quarters has been encouraging.,positive,positive,0.7795534272509606,neutral,-0.021973192704905,neutral
2018-05-14 23:00:24.776,828.0,932.5,825.0,892.0,1135088.0,Dr Lal PathLabs Q4 net up 27%,"Diagnostic chain Dr Lal PathLabs today reported 27.20 per cent rise in consolidated net profit to ₹ 40.2 crore for the quarter ended March 31, 2018. The company had posted a net profit of Rs 31.6 cror",positive,positive,7.729468599033816,positive,0.4633291897389561,neutral
2018-05-14 23:00:43.923,828.0,932.5,825.0,892.0,1135088.0,Dr Lal PathLabs Q4 net up 27% at Rs 40 cr,"Diagnostic chain Dr Lal PathLabs today reported 27.21 per cent rise in consolidated net profit to Rs 40.2 crore for the quarter ended March 31, 2018. The company had posted a net profit of Rs 31.6 cro",positive,positive,7.729468599033816,positive,0.4633291897389561,neutral
2018-05-15 18:01:01.589,884.9,909.0,856.05,889.0,227829.0,Dr Lal PathLabs shares surge over 10% after Q4 results,Dr Lal PathLabs shares rises 10.06% to close at Rs887.20 on BSE after the company reports a 27.21% rise in its consolidated net profit for the March 2018 quarter,positive,positive,0.4633291897389561,neutral,-2.699662542182227,negative
2018-07-10 18:00:33.069,897.7,910.0,895.85,904.0,32181.0,Dr Lal PathLabs stock falls 3% after its chief financial officer resigns,Bidani will now be serving his notice period in the company.,negative,neutral,0.7017934722067455,neutral,-0.9038800705467422,negative
2018-08-27 10:00:33.771,1028.65,1088.7,1016.0,1077.9,182630.0,"Pricing pressures, regulatory worries for Dr Lal Pathlabs and Thyrocare","While the organised sector is gaining market share, there are near-term challenges for Dr Lal Pathlabs and Thyrocare",negative,positive,4.787828707529285,positive,-1.1284155553483082,negative
2018-11-05 23:01:21.183,908.0,909.95,874.0,876.9,92307.0,"Voltas, Manappuram, Graphite Ind results","About 40 companies including Aditya Birla Capital, ABC India, Automotive Axles, Balmer Lawrie Inv, Camlin Fine Sciences, Cupid, Dr Lal PathLabs, Eon Electric, Garware Polyester, Goldcrest, Graphite In",neutral,neutral,-3.425110132158593,negative,0.3401360544217687,neutral
2018-11-07 10:31:21.431,882.0,895.0,880.0,885.0,3902.0,Dr Lal PathLabs reports 12.8% jump in net profit at Rs 574 million,Operating margin declined to 28.5 per cent as against 29 per cent a year ago,positive,negative,0.3401360544217687,neutral,-3.3860045146726865,negative
2019-04-02 13:01:07.539,1052.8,1057.95,1035.0,1038.0,23521.0,Dr Lal PathLabs gains 3% on acquisition of Bawankar Pathology,"At 1015 hrs, Dr Lal PathLabs was quoting Rs 1076, up 2.81 percent on the BSE.",positive,positive,-1.4057750759878376,negative,-2.200956937799043,negative
2019-04-03 13:02:26.917,1045.0,1045.0,1020.0,1022.0,27293.0,"Metropolis Healthcare's Rs 1,200-crore IPO opens; should you subscribe?","Considering its better operating metrics, attractive valuations which are justifiable to listed peer Dr Lal Pathlabs, brokerages advise subscribing the issue for listing gains as well as for long term",neutral,positive,-2.200956937799043,negative,1.696582247356774,positive
2019-04-16 10:00:54.520,1065.5,1080.0,1045.2,1053.0,28744.0,Metropolis Healthcare shares gain 9% over issue price on debut,"On a price-to-earnings (P/E) valuation basis, analysts said Metropolis is cheaper than Dr Lal Pathlabs",positive,neutral,-1.1731581417175034,negative,2.099236641221374,positive
2019-04-17 18:01:27.788,1048.0,1073.55,1042.0,1070.0,34666.0,Dr Lal Pathlabs Q4 PAT seen up 28.3% YoY to Rs. 51.4 cr: Kotak,"Net Sales are expected to increase by 15.3 percent Y-o-Y (up 5.2 percent Q-o-Q) to Rs. 307.7 crore, according to Kotak.",positive,positive,2.099236641221374,positive,0.0851385866994694,neutral
2019-06-14 18:00:39.982,1089.0,1108.95,1065.2,1075.6,386963.0,Dr Lal PathLabs to acquire 70% stake in a new company,Company's board has approved signing a binding term sheet for the acquisition.Indicative time period for completion of acquisition is within three months,neutral,neutral,-1.230486685032148,negative,-1.098901098901099,negative
2019-07-15 18:00:50.849,1056.5,1080.25,1035.05,1079.0,104799.0,Dr Lal Pathlabs Q4 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak,"Net Sales are expected to increase by 14 percent Y-o-Y (up 10.7 percent Q-o-Q) to Rs. 333.2 crore, according to Kotak.",positive,positive,2.1296734500709893,positive,1.1209302325581352,positive
2019-07-21 23:00:54.570,1066.3,1109.45,1055.1,1103.0,26118.0,"Preventive testing, Ayushman Bharat to drive diagnostic firms' revenues","Diagnostic services companies led by Dr Lal Pathlabs, Metropolis Healthcare have outperformed the market and this trend is expected to sustain",neutral,positive,3.4418081215417846,positive,0.5865238073246116,neutral
2019-10-01 23:02:38.577,1398.2,1398.2,1311.0,1338.0,98259.0,Dr Lal PathLabs to acquire 70 pc stake in Amins Pathology Referral Laboratory,The acquisition will further strengthen the company's network in Gujarat and adjoining areas,neutral,positive,-4.305535688742673,negative,2.900223380491441,positive
2019-10-09 13:00:26.793,1336.0,1423.0,1336.0,1365.1,133251.0,"3 stocks are in the pink of health in a choppy market, drawing eyeballs",Shares of Dr Lal Pathlabs have posted an impressive 52.45 per cent gain since the start of 2019.,neutral,positive,2.1781437125748435,positive,0.6578947368421052,neutral
2019-10-11 18:01:41.246,1368.0,1384.95,1336.0,1377.0,158558.0,Dr Lal Pathlabs Q2 PAT seen up 48.8% YoY to Rs. 84.8 cr: Kotak,"Net Sales are expected to increase by 14.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 364.5 crore, according to Kotak.",positive,positive,0.6578947368421052,neutral,0.9624114763028871,positive
2019-11-11 10:01:24.342,1485.0,1507.75,1470.0,1480.0,307037.0,Dr Lal PathLabs share price up 4% on better Q2 nos; brokerages maintain buy,"The earnings before interest, tax, depreciation and amortisation (EBITDA) was up 25.5 percent at Rs 109 crore, While EBITDA margin was up 250 bps at 29.8 percent.",positive,positive,-0.3367003367003366,neutral,1.7567567567567568,positive
2020-02-03 10:02:12.497,1761.0,1830.0,1710.0,1722.0,288584.0,"Board Meetings Today: GSK Pharma, Ujjivan Financial, Affle India, Godrej Properties and Shriram Transport","Dr Lal Pathlabs, Bayer Cropscience and Tata Chemicals are some of the companies which will report their December quarter earnings today.​​",neutral,neutral,-2.2146507666098807,negative,-3.1800113571834183,negative
2020-02-03 18:02:18.744,1761.0,1765.1,1687.3,1705.0,262654.0,Dr Lal PathLabs Q3 net up 19 per cent to ₹55 cr,"Diagnostic services provider Dr Lal PathLabs on Monday reported a 19.08 per cent increase in consolidated net profit at ₹54.9 crore for the quarter ended December 31, 2019.The company had posted a net",neutral,positive,-3.1800113571834183,negative,-1.282798833819242,negative
2020-02-03 18:02:23.316,1761.0,1765.1,1687.3,1705.0,262654.0,Dr Lal PathLabs Q3 net profit up 19% to Rs 54.9 crore,Its revenue from operations rose to Rs 327.9 crore during the quarter under review.,positive,positive,-3.1800113571834183,negative,-1.282798833819242,negative
2020-02-03 18:04:10.131,1761.0,1765.1,1687.3,1705.0,262654.0,Dr Lal PathLabs Q3 net profit up 19% to Rs 54.9cr,"The company had posted a net profit of Rs 46.1 crore in the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to the BSE.

",positive,positive,-3.1800113571834183,negative,-1.282798833819242,negative
2020-02-05 10:02:15.880,1715.0,1737.8,1676.45,1693.0,73206.0,Broker's call: Dr Lal PathLabs,"JMFLDr Lal PathLabs (Buy)CMP: ₹1,701Target: ₹1,750Dr Lal PathLabs reported a muted performance in 3QFY20 with sub-par growth of 2 per cent in the Delhi NCR market even as growth in the Rest of India (",neutral,negative,-1.282798833819242,negative,-4.213649851632048,negative
2020-02-25 10:04:49.926,1651.0,1686.2,1640.0,1653.0,152814.0,"Board Meetings Today: Asian Paints, Dr Lal Pathlabs, Navin Fluorine, Sanofi India and Wonderla Holidays",It makes sense to have a look at the corporate agendas for the days as announced to the stock exchanges. ,neutral,neutral,0.1211387038158691,neutral,-0.2424242424242424,neutral
2020-03-18 13:04:57.967,1420.0,1440.0,1252.15,1346.45,400576.0,"Thyrocare Tech, Dr Lal PathLabs rise 9% as govt allow private lab to do coronavirus testing","The total number of coronavirus cases in India rose to 147, with 10 fresh cases reported from various parts of the country.",positive,positive,-5.179577464788729,negative,5.029585798816568,positive
2020-04-17 06:00:00.000,1529.0,1550.0,1508.0,1523.0,149467.0,Dr. Lal PathLabs shares surge 3.54% on stable outlook,"CRISIL has also confirmed that such letter will remain valid till March 31, 2021.",positive,neutral,-0.3924133420536298,neutral,-3.6368889031554,negative
2020-04-17 08:20:00.000,1529.0,1550.0,1508.0,1523.0,149467.0,"In pics | Stocks in the news: TCS, M&M, Deepak Fertilizers, JK Lakshmi Cement, Greenply Industries",Oberoi Realty | ASI Industries | Dr Lal Pathlabs | Grindwell Norton | Evans Electric | Ambala Sarabhai Enterprises | Tata Motors | TCS | Sudarshan Chemical Industries are among the stocks in the news today.,neutral,neutral,-0.3924133420536298,neutral,-3.6368889031554,negative
2020-04-21 08:03:21.000,1476.0,1510.0,1461.05,1476.05,100805.0,Broker’s call: Dr Lal PathLabs (Buy),"Geojit Financial ServicesDr Lal PathLabs (Buy)CMP: ₹1,500Target: ₹1,762Dr Lal PathLabs Ltd (DLPL) offers diagnostic and related healthcare tests and services in India and internationally. Company had",neutral,neutral,0.0033875338753356,neutral,-0.1349527665317139,neutral
2020-04-21 13:09:00.000,1482.0,1498.8,1445.0,1480.0,164345.0,"Buy Dr Lal Pathlabs, target price Rs 1,762: Geojit",The company is well placed to benefit from increased demand for coronavirus testing in the medium-term.,neutral,positive,-0.1349527665317139,neutral,-0.6594663705797217,neutral
2020-05-11 07:45:00.000,1553.0,1573.55,1542.95,1558.0,72351.0,"In pics | Stock in the news: Apollo Pipes, Dr Lal PathLabs, Lupin, VIP Industries","Sobha, TCI Express, Magma Fincorp and NOCIL are some of the stocks in focus today.",neutral,neutral,0.3219575016097875,neutral,1.48005148005148,positive
2020-05-18 03:45:00.000,1595.9,1615.0,1562.0,1581.8,388217.0,Dr Lal PathLabs Q4 PAT declines 31% to Rs32.6cr; revenue stable,"Consolidated net profit decelerated to Rs32.6cr in Q4, compared to Rs47.4cr a year ago same period.",negative,positive,-0.8835140046368906,neutral,0.1948051948051948,neutral
2020-05-18 05:30:00.000,1595.9,1615.0,1562.0,1581.8,388217.0,BRIEF-Dr. Lal Pathlabs March Qtr Consol Net Profit Falls - Investing.com India,"The Financial News section features stock market news in addition to stories about bonds, forex, commodities and economic releases.",neutral,neutral,-0.8835140046368906,neutral,0.1948051948051948,neutral
2020-05-18 08:29:00.000,1595.9,1615.0,1562.0,1581.8,388217.0,"Board Meetings Today: Vedanta, Bharti Airtel, Torrent Pharma, Delta Corp and GSK Pharma","Astrazeneca Pharma, Dr Lal Pathlabs and Monnet Ispat are among a few companies which will announce their March quarter results on Monday.",neutral,neutral,-0.8835140046368906,neutral,0.1948051948051948,neutral
2020-05-18 08:55:35.000,1595.9,1615.0,1562.0,1581.8,388217.0,"Stocks in focus: RIL, Bharti Airtel, Maruti Suzuki, Coal India to remain in action today","GSK Pharma, Delta Corp, Bharti Airtel, Gujarat Themis Biosyn, Dr Lal PathLabs, Torrent Pharma are among 14 companies which are scheduled to announce their March quarter results later in the day today",neutral,neutral,-0.8835140046368906,neutral,0.1948051948051948,neutral
2020-05-18 15:55:00.000,1540.0,1580.0,1508.25,1543.0,229922.0,"Share Market Update: Sensex ends 1,068 points lower, Nifty at 8,823; IndusInd Bank, Zee Ent top losers","Dalal Street today: Bharti Airtel, Torrent Power, Glaxosmithkline Pharmaceuticals, Astrazeneca Pharma, Maharashtra Scooters, Dr. Lal PathLabs, Gujarat Themis Biosyn, Delta Corp, Deccan Gold Mines, Allsec Technologies are among the top companies that will",negative,neutral,0.1948051948051948,neutral,0.8430609597924773,neutral
2020-05-18 17:38:00.000,1540.0,1580.0,1508.25,1543.0,229922.0,Dr Lal PathLabs Q4 results: Net profit declines 31% to Rs 32.6 crore,The company had posted a net profit of Rs 47.4 crore for the corresponding period of previous fiscal.,negative,positive,0.1948051948051948,neutral,0.8430609597924773,neutral
2020-05-19 10:51:00.000,1540.0,1580.0,1508.25,1543.0,229922.0,Trending stocks: Dr. Lal Pathlabs shares down over 2%,"A total of 1,483 shares changed hands on the counter till 10:48AM (IST).",negative,neutral,0.1948051948051948,neutral,0.8430609597924773,neutral
2020-05-19 11:05:00.000,1540.0,1580.0,1508.25,1543.0,229922.0,Sell Dr. Lal PathLabs; target of Rs 895: Prabhudas Lilladher,"Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 895 in its research report dated May 19, 2020.",neutral,positive,0.1948051948051948,neutral,0.8430609597924773,neutral
2020-05-19 13:48:00.000,1542.0,1570.0,1533.4,1555.0,95092.0,"Nomura downgrades Dr Lal PathLabs to reduce, cuts target price","We think the near-term earnings outlook remain challenging, said Nomura.",negative,negative,0.8430609597924773,neutral,-3.189757016507554,negative
2020-05-19 23:45:19.000,1542.0,1570.0,1533.4,1555.0,95092.0,"Maintain ‘hold’ on Dr Lal PathLabs with TP of Rs 1,600","In this environment, while management has been focusing on costs in terms of rental arrangements, travel, overtime and hiring, expect net cost of operations to rise on account of extensive use of masks and PPEs.",neutral,positive,0.8430609597924773,neutral,-3.189757016507554,negative
2020-05-20 06:00:00.000,1542.0,1570.0,1533.4,1555.0,95092.0,Broker’s call: Dr Lal PathLabs (Add),"ICICI SecuritiesDr Lal PathLabs (Add)CMP: ₹1,550.35Target: ₹1,710Dr Lal PathLabs is engaged in the business of running laboratories for carrying out pathological investigations of various branches of",neutral,neutral,0.8430609597924773,neutral,-3.189757016507554,negative
2020-05-20 08:15:00.000,1542.0,1570.0,1533.4,1555.0,95092.0,"Add Dr Lal Pathlabs, target price Rs 1,710: ICICI Securities","The brokerage expects Dr Lal to outperform industry growth and register revenue, EBITDA and PAT growth at CAGRs of 11.9 per cent, 16.1 per cent and 21.8 per cent, respectively, over FY20-FY22E.",neutral,positive,0.8430609597924773,neutral,-3.189757016507554,negative
2020-06-02 05:30:00.000,1525.0,1542.75,1513.2,1519.5,86945.0,BRIEF-Dr. Lal Pathlabs Says Adverse Impact Of Lockdown On Co’s Revenue Seen Until Q2 FY21 - Investing.com India,"The Financial News section features stock market news in addition to stories about bonds, forex, commodities and economic releases.",neutral,neutral,-0.360655737704918,neutral,0.5770816158285244,neutral
2020-07-07 16:01:00.000,1732.0,1775.0,1732.0,1775.0,399712.0,Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs,The company said it served 1.94 crore patients and processed 4.77 crore samples,positive,neutral,2.4826789838337184,positive,2.924634420697413,positive
2020-07-08 11:02:00.000,1732.0,1775.0,1732.0,1775.0,399712.0,Trending stocks: Dr. Lal Pathlabs shares climb over 2%,"A total of 1,892 shares changed hands on the counter till 10:58AM (IST).",positive,neutral,2.4826789838337184,positive,2.924634420697413,positive
2020-07-13 12:16:09.000,1882.9,1926.05,1854.0,1898.0,217048.0,Caplin Point Laboratories Ltd leads gainers in ‘A’ group,"Hathway Cable & Datacom Ltd, Reliance Industries Ltd Partly Paidup, Dr Lal Pathlabs Ltd and Thyrocare Technologies Ltd are among the other gainers in the BSEs A group today, 13 July 2020.",positive,neutral,0.8019544319931972,neutral,-0.2103049421661409,neutral
2020-07-13 13:00:00.000,1882.9,1926.05,1854.0,1898.0,217048.0,"Healthcare services stocks in focus; Dr Lal PathLabs, Thyrocare up over 5%","Metropolis Healthcare, meanwhile, rallied 7% to Rs 1,579 today, and were trading higher for the eighth straight day",positive,positive,0.8019544319931972,neutral,-0.2103049421661409,neutral
2020-07-14 08:04:00.000,1882.9,1926.05,1854.0,1898.0,217048.0,"Trade Spotlight: Dixon Tech, Britannia, L&T Infotech, Dr Lal & Escorts in focus","Dixon Technologies, Britannia Industries, L&amp;T Infotech, Dr Lal Pathlabs &amp; Escorts are some of the stocks that hit a fresh 52-week high on July 13.",neutral,neutral,0.8019544319931972,neutral,-0.2103049421661409,neutral
2020-07-15 11:44:00.000,1902.0,1938.0,1875.0,1898.0,149305.0,"Infosys, HCL Tech, L&T Infotech, Granules, Laurus Labs hit record highs","Reliance Industries, Larsen & Toubro Infotech and Dr Lal Pathlabs from S&P BSE500 index hit record highs today.",positive,positive,-0.2103049421661409,neutral,-2.388685175484542,negative
2020-07-15 18:36:00.000,1909.0,1940.0,1845.0,1863.4,152292.0,Dr Lal PathLabs shares extend gains into 3rd day; analysts positive on firm’s long term story,"Despite the turmoil caused by COVID-19, the stock has been gaining significantly in the calendar year 2020 so far. The stock has gained 27 percent as of July 14 close on BSE against a 13 percent fall in benchmark Sensex.",positive,positive,-2.388685175484542,negative,0.1341561577676415,neutral
2020-07-16 18:14:00.000,1863.5,1899.9,1838.05,1866.0,110858.0,"Taking Stock: IT stocks help bulls put up a smart show; Nifty back above 10,700","TCS, L&T Infotech, Dr. Lal Pathlabs, and Infosys were among the 100 stocks that hit a new 52-week high.",neutral,positive,0.1341561577676415,neutral,2.907319162606412,positive
2020-07-31 02:39:00.000,1895.0,1962.0,1862.85,1878.0,435033.0,Dr. Lal Pathlabs Q1FY21; consolidated profit decline by ~52% yoy,The company recorded a consolidated profit of Rs28.4cr in Q1FY21.,negative,positive,-0.8970976253298154,neutral,-0.0533333333333333,neutral
2020-07-31 05:30:00.000,1895.0,1962.0,1862.85,1878.0,435033.0,BRIEF-India’s Dr. Lal Pathlabs June Qtr Consol Net Profit Falls - Investing.com India,"The Financial News section features stock market news in addition to stories about bonds, forex, commodities and economic releases.",neutral,neutral,-0.8970976253298154,neutral,-0.0533333333333333,neutral
2020-07-31 15:06:00.000,1895.0,1962.0,1862.85,1878.0,435033.0,Dr Lal PathLabs Q1 profit falls 52% to Rs 28.4 crore,Its revenue was down 20.6% at Rs 266 crore against Rs 335.2 crore.,negative,negative,-0.8970976253298154,neutral,-0.0533333333333333,neutral
2020-07-31 16:24:00.000,1895.0,1962.0,1862.85,1878.0,435033.0,Dr Lal PathLabs Q1 results: Net profit declines 52% to Rs 28.4 crore,"The company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to BSE.",negative,positive,-0.8970976253298154,neutral,-0.0533333333333333,neutral
2020-07-31 17:17:00.000,1895.0,1962.0,1862.85,1878.0,435033.0,Dr Lal PathLabs June quarter net profit declines 52% to Rs 28.4 crore,"Diagnostic services provider Dr Lal PathLabs on Friday reported a 51.94 per cent decline in its consolidated net profit at Rs 28.4 crore for the quarter ended June 30, 2020.",negative,negative,-0.8970976253298154,neutral,-0.0533333333333333,neutral
2020-07-31 22:58:00.000,1895.0,1962.0,1862.85,1878.0,435033.0,Dr Lal PathLabs Q1 net profit declines 52% amid COVID-19,"Diagnostic services provider Dr Lal PathLabs on Friday reported a 51.94 per cent decline in its consolidated net profit at Rs 28.4 crore for the quarter ended June 30, 2020.The company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal Path…",negative,negative,-0.8970976253298154,neutral,-0.0533333333333333,neutral
2020-08-04 17:31:00.000,1835.0,1880.0,1835.0,1846.4,98104.0,Margin pressures to cap upside for Dr Lal Pathlabs as Covid dents volumes,Valuations too do not leave much scope for gains,positive,neutral,0.6212534059945554,neutral,0.3735787763941576,neutral
2020-08-09 17:52:00.000,1912.0,1922.0,1867.55,1875.1,98554.0,Margin pressures likely to cap upside for Dr Lal Pathlabs: Analysts,"Valuations, too, do not leave much scope for gains",positive,neutral,-1.9299163179916363,negative,-1.113467656415695,negative
2020-08-27 08:18:00.000,1858.9,1859.75,1846.0,1857.0,52134.0,These companies’ operating cash flow consistently increasing since last 3 fiscal years; do you own any?,"Stocks like Alkyl Amines Chemicals, Avenue Supermarts, Diamines & Chemicals, Dr. Lal Pathlabs have gained over 100 percent in the past three years.",positive,positive,-0.1022109849911286,neutral,-1.648116438356162,negative
2020-10-07 11:00:00.000,2000.0,2330.0,1936.0,2210.0,1498249.0,Healthcare services stocks rally; Thyrocare up 35% in 2 days post Q2 update,"Thyrocare Technologies, Metropolis Healthcare and Dr. Lal PathLabs, hitting their respective record highs, were up 9 per cent to 17 per cent on the BSE in intra-day trade.",positive,positive,10.5,positive,-2.589114778010765,negative
2020-10-07 12:04:05.000,2193.8,2193.8,2125.4,2137.0,416833.0,Thyrocare Technologies Ltd leads gainers in ‘A’ group,"Metropolis Healthcare Ltd, Take Solutions Ltd, Dr Lal Pathlabs Ltd and Reliance Industries Ltd Partly Paidup are among the other gainers in the BSEs A group today, 07 October 2020.",positive,neutral,-2.589114778010765,negative,-2.333333333333333,negative
2020-10-08 08:39:00.000,2193.8,2193.8,2125.4,2137.0,416833.0,"Trade Spotlight: Metropolis Healthcare, Dr Lal Pathlabs & Ambuja Cement in focus","Dr Lal Pathlabs gained more than 11 percent, Metropolis Healthcare was up more than 4 percent and Ambuja Cement which hit a 52-week high closed with gains of more than 4 percent.",neutral,positive,-2.589114778010765,negative,-2.333333333333333,negative
2020-10-08 12:34:00.000,2100.0,2180.0,2047.1,2051.0,452771.0,"Book profit now! After solid rally, red flag goes up on these stocks","Shares of three key listed diagnostics companies – Thyrocare Technologies, Metropolis Healthcare and Dr Lal Pathlabs – hit their respective record highs of Rs 1,061, Rs 2,146.50 and Rs 2,329.80 on Wednesday.",positive,positive,-2.333333333333333,negative,6.470588235294119,positive
2020-10-09 10:29:00.000,2100.0,2180.0,2047.1,2051.0,452771.0,"Data of millions of Dr Lal PathLabs patients exposed, including address, phone numbers, email ids",Dr Lal PathLabs had stored the data in a bucket hosted on Amazon Web Services without a password. Cybersecurity expert Sami Toivonen said that it is unclear if any malicious actors accessed the data,neutral,neutral,-2.333333333333333,negative,6.470588235294119,positive
2020-10-09 20:44:00.000,2100.0,2180.0,2047.1,2051.0,452771.0,"Dr Lal PathLabs exposed data of millions of patients, including COVID-19 test results: Report","The data included patients’ booking details such as their name, address, phone number, email id, payment details, digital signature, and also the type of medical tests they had taken.",neutral,neutral,-2.333333333333333,negative,6.470588235294119,positive
2020-10-12 05:17:00.000,2040.0,2210.0,2010.95,2172.0,499884.0,Dr Lal PathLabs stock ends higher post clarification on exposed data,"There was a misconfiguration in one of our minor web application where temporary records were stored for operational purposes and took place at a facility managed by a third party, the company said.",positive,neutral,6.470588235294119,positive,-2.258287292817688,negative
2020-10-12 10:02:00.000,2040.0,2210.0,2010.95,2172.0,499884.0,Dr Lal PathLabs issues clarification on data leak,The media reported that Dr Lal PathLabs exposed the personal data of millions of patients in the public domain making it accessible to everyone last month.,neutral,neutral,6.470588235294119,positive,-2.258287292817688,negative
2020-10-14 08:13:26.000,2130.0,2141.15,2046.0,2060.0,181585.0,"Upgrade Dr Lal Pathlabs to ‘neutral’ with TP of Rs 2,155",We note that EBITDA contribution from Covid-19 tests was much higher than we had previously estimated due to high volumes and a drop in raw material costs.,neutral,positive,-3.286384976525822,negative,-1.3062409288824384,negative
2020-11-06 05:30:00.000,2331.0,2377.8,2265.0,2270.0,187171.0,BRIEF-Dr. Lal Pathlabs - Unit To Buy Bindish Diagnostic Lab On Going Concern Basis - Investing.com India,"The Financial News section features stock market news in addition to stories about bonds, forex, commodities and economic releases.",neutral,neutral,-2.616902616902617,negative,-1.240225890529982,negative
2020-11-06 09:45:00.000,2331.0,2377.8,2265.0,2270.0,187171.0,Dr. Lal Pathlabs arm signs agreement to acquire business of BDL and CDSPL,PathLabs Unifiers will purchase Bindish Diagnostic Lab’s Jamnagar business for ~Rs40 million and in ChanRe Diagnostic in Bengaluru for Rs175 million.,positive,neutral,-2.616902616902617,negative,-1.240225890529982,negative
2020-11-06 15:07:00.000,2331.0,2377.8,2265.0,2270.0,187171.0,Dr Lal Pathlabs announces acquisition of two pathology labs,Powered by Capital Market - Live News,positive,neutral,-2.616902616902617,negative,-1.240225890529982,negative
2020-11-06 15:20:00.000,2331.0,2377.8,2265.0,2270.0,187171.0,"Dr Lal PathLabs’ Q2 net profit rises 6%, revenue up 18% YoY","Consolidated revenue for the said quarter came at Rs 431.9 crore, up 18 percent YoY from Rs 365.6 crore in the corresponding quarter of the previous financial year.",positive,positive,-2.616902616902617,negative,-1.240225890529982,negative
2020-11-06 15:37:00.000,2331.0,2377.8,2265.0,2270.0,187171.0,Dr Lal Pathlabs consolidated net profit rises 5.96% in the September 2020 quarter,Sales rise 18.13% to Rs 431.90 crore,positive,positive,-2.616902616902617,negative,-1.240225890529982,negative
2020-11-06 17:05:00.000,2331.0,2377.8,2265.0,2270.0,187171.0,Dr Lal PathLabs Q2 results: Net profit up 7.5% to Rs 87 cr,"Revenue from operations stood at Rs 431.9 crore for the quarter under consideration. It was Rs 365.6 crore for the same period a year ago, it added.​​",positive,neutral,-2.616902616902617,negative,-1.240225890529982,negative
2020-11-10 11:30:00.000,2260.0,2263.2,2093.0,2141.3,397198.0,"Dr Lal PathLabs, Thyrocare slip on profit booking on Covid vaccine optimism","From March lows, the stock price of Thyrocare Technologies has been more-than-tripled and of Dr Lal PathLabs more-than-doubled on the BSE",negative,positive,-5.252212389380523,negative,1.1655011655011656,positive
2020-11-10 15:04:38.000,2145.0,2205.25,2132.05,2170.0,99788.0,Ipca Laboratories Ltd leads losers in ‘A’ group,"Thyrocare Technologies Ltd, Larsen & Toubro Infotech Ltd, Muthoot Finance Ltd and Dr Lal Pathlabs Ltd are among the other losers in the BSEs A group today, 10 November 2020.",neutral,negative,1.1655011655011656,positive,0.4644681839294008,neutral
2020-11-23 10:52:00.000,2219.65,2328.75,2186.9,2270.0,206535.0,"Pharma shares in focus; Divi’s Labs hits new high, Gland Pharma zooms 20%","Dishman Carbogen Amcis, Ipca Lab, SPARC, Caplin Point Laboratories, Dr. Lal PathLabs and Granules India from the S&P BSE Healthcare index were up in the range of 4 per cent to 5 per cent on the BSE",neutral,positive,2.268375644808862,positive,-2.1779405428694605,negative
2020-11-24 11:05:00.000,2321.0,2374.7,2260.1,2270.45,164411.0,"Dr Lal PathLabs, Metropolis: How healthcare firms’ stocks look on charts","Thyrocare Technologies has the strong support of 50-DMA, currently placed at Rs 988 levels.",neutral,positive,-2.1779405428694605,negative,-1.3686534216335542,negative
2020-12-01 07:52:00.000,2290.5,2302.25,2261.2,2269.15,104290.0,"Nifty outlook & trading strategies by CapitalVia: Buy SBI, Dr Lal PathLabs",Better-than-expected Q2 GDP data numbers might help index to move in the positive territory,neutral,positive,-0.932110892818158,negative,-0.9653356735410268,negative
2020-12-09 11:04:10.000,2245.95,2249.0,2170.0,2175.0,429346.0,Volumes soar at Dr Lal Pathlabs Ltd counter,"Dr Lal Pathlabs Ltd clocked volume of 2 lakh shares by 10:48 IST on BSE, a 55.57 times surge over two-week average daily volume of 3607 shares",neutral,positive,-3.159019568556728,negative,-0.9111617312072892,negative
2021-01-18 23:05:22.000,2235.0,2295.5,2212.0,2295.5,96951.0,Dr. Lal PathLabs Q3 PAT Seen Up 27.4% YoY To Rs. 54.1 Cr: Prabhudas Lilladher,"Net Sales are expected to increase by 16.1 percent Y-o-Y (down 11.8 percent Q-o-Q) to Rs. 327.9 crore, according to Prabhudas Lilladher.",neutral,positive,2.7069351230425056,positive,0.7493755203996629,neutral
2021-01-31 17:27:17.000,2270.0,2320.0,2212.0,2305.0,202422.0,Dr. Lal Pathlabs Maintains Superior Execution In Q3: ICICI Securities,Dr. Lal Pathlabs Maintains Superior Execution In Q3: ICICI Securities,neutral,neutral,1.5418502202643172,positive,5.172782482251317,positive
2021-02-01 07:59:31.000,2270.0,2320.0,2212.0,2305.0,202422.0,"Budget 2021 Stocks In The News | Shree Cement, ICICI Bank, Tata Motors, Tech Mahindra, Cipla, DLF","Titan Company, IndusInd Bank, Vedanta, Bajaj Healthcare, Jaiprakash Associates, EIH, JK Lakshmi Cement, Sundaram-Clayton, Mahindra Logistics, Rupa & Company, Dr Lal PathLabs are also among the stocks in focus today.",neutral,neutral,1.5418502202643172,positive,5.172782482251317,positive
2021-02-17 13:49:10.000,2617.6,2620.0,2481.0,2492.95,367299.0,"D-Street Buzz: Over 200 Stocks Hit 52-week High On BSE; Bank Of Maharashtra, IOB Hit Upper Circuit","217 stocks have hit new 52-week high on BSE including names like Bank of Maharashtra, Indian Overseas Bank, Bank of India, Dr Lal Pathlabs, Indian Bank, IDFC First Bank, Adani Transmission, Adani Ports, Avenue Supermarts, Tata Consumer and Hindalco Industries among others.",neutral,neutral,-4.761995721271398,negative,-1.725521669341894,negative
2021-02-17 17:40:00.000,2617.6,2620.0,2481.0,2492.95,367299.0,"Market Movers: What spurred rally in NCC, Dr Lal Pathlabs","Despite a weakness in the headline indices, as many as 40 stocks on the National Stock Exchange gave buy signal based on MACD indicators.",positive,positive,-4.761995721271398,negative,-1.725521669341894,negative
2021-03-24 02:48:00.000,2558.8,2585.7,2461.8,2478.1,147420.0,"Sales recovery, expansion in new markets key to Dr Lal Pathlabs’ growth","Higher competition, expansion may be a challenge for margin",positive,positive,-3.1538221041113124,negative,0.0745967741935447,neutral
2021-03-30 11:58:00.000,2600.0,2689.5,2589.4,2616.3,354041.0,Sensex surges! Stocks that gained over 10%,"​Stocks such as Tata Steel BSL, Orchid Pharma , Tata Steel, JSW Steel, Shree Cements, Adani Transmission, Dr Lal Pathlabs, Godrej Industries, Prism Johnson and 3M India hit their fresh 52-week high in today’s trade.",positive,positive,0.6269230769230839,neutral,2.6382315485354635,positive
2021-03-30 13:03:00.000,2630.55,2736.0,2614.2,2699.95,518906.0,Sensex soars! But these stocks fell 5% or more,"Meanwhile, Tata Steel BSL, Orchid Pharma, JSW Steel, Tata Steel, Shree Cements, Adani Transmission, Godrej Ind., Prism Johnson, Dr Lal Pathlabs and 3M India touched their fresh 52-week high today.",negative,neutral,2.6382315485354635,positive,1.0250087410978783,positive
2021-04-05 11:16:00.000,2772.0,2925.0,2720.0,2898.0,940761.0,Dr Lal PathLabs hits record high in a weak market; surges 19% in 5 days,"The company would continue to reap benefits from increased Covid-related and allied testing in its widespread network of diagnostic centers and labs, analysts believe",positive,positive,4.545454545454546,positive,5.15859423169144,positive
2021-04-05 11:43:00.000,2772.0,2925.0,2720.0,2898.0,940761.0,Sensex tanks! But these stocks are up 10%,"​Stocks such as Dr Lal Pathlabs, Happiest Minds, AGC Networks, Adani Transmission, Adani Gas, SAIL, Infosys, Adani Ent., Atul and JSW Steel hit their fresh 52-week high in today’s trade.",positive,positive,4.545454545454546,positive,5.15859423169144,positive
2021-04-05 12:04:05.000,2919.4,3090.35,2885.0,3070.0,769874.0,NIIT Ltd leads gainers in ‘A’ group,"Future Consumer Ltd, Dr Lal Pathlabs Ltd, Neuland Laboratories Ltd and Future Supply Chain Solutions Ltd are among the other gainers in the BSE’s ‘A’ group today, 05 April 2021.",positive,neutral,5.15859423169144,positive,-2.810064935064941,negative
2021-04-05 12:43:42.000,2919.4,3090.35,2885.0,3070.0,769874.0,Diagnostic firms gain amid rise in covid cases,"Thyrocare Technologies surged 5.4%, Metropolis Healthcare rose 4% while Dr Lal PathLabs gained 6%, Fortis Healthcare advanced 3%.",positive,positive,5.15859423169144,positive,-2.810064935064941,negative
2021-04-05 19:30:00.000,2919.4,3090.35,2885.0,3070.0,769874.0,Stocks of diagnostic chains factoring in near-term positives: Analysts,"They say it will be a good strategy to exit these stocks at least for now. Over the long-run, however, Dr Lal Pathlabs, Metropolis Healthcare and Thyrocare Tech still offer room for growth",positive,positive,5.15859423169144,positive,-2.810064935064941,negative
2021-04-06 08:08:38.000,2919.4,3090.35,2885.0,3070.0,769874.0,"Trade Spotlight: What Should Investors Do With Dr Lal Pathlabs, IndusInd Bank, & Happiest Minds?","Dr Lal Pathlabs gained over 6 percent with strong volumes, IndusInd Bank fell nearly 6 percent, and Happiest Minds rallied over 4 percent to hit a fresh 52-week high on April 5.",neutral,positive,5.15859423169144,positive,-2.810064935064941,negative
2021-04-12 10:50:00.000,3154.0,3399.3,3120.0,3309.4,2039155.0,"Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs",Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade,positive,positive,4.927076727964493,positive,-11.244377811094452,negative
2021-04-13 15:04:18.000,3335.0,3359.9,2905.0,2960.0,1578005.0,Dr Lal Pathlabs Ltd leads losers in ‘A’ group,"Coforge Ltd, Paisalo Digital Ltd, L&T Technology Services Ltd and Yaarii Digital Integrated Services Ltd are among the other losers in the BSE’s ‘A’ group today, 13 April 2021.",negative,negative,-11.244377811094452,negative,-4.350670592083742,negative
2021-04-15 05:30:00.000,3057.0,3060.0,2901.0,2924.0,1291268.0,Dr Lal Pathlabs Downgraded by Nomura,Dr Lal Pathlabs Downgraded by Nomura,neutral,neutral,-4.350670592083742,negative,-0.9542372881355964,negative
2021-04-15 08:36:29.000,3057.0,3060.0,2901.0,2924.0,1291268.0,"Downgrade Dr Lal PathLabs to ‘reduce’ with TP at Rs 2,333","DLPL stock has significantly outperformed its peers and the broader market since the start of the pandemic. Since mid-Feb 2020 (when fear pandemic started), the stock is up 106% against a Nifty return of 18%.",neutral,positive,-4.350670592083742,negative,-0.9542372881355964,negative
2021-04-16 13:19:00.000,2950.0,3021.15,2908.0,2921.85,725614.0,Red flag goes up on diagnostic stock after Covid 2.0 lifted it 51% in 2 months,"The latest brokerage to give such a call is Nomura, which on Tuesday downgraded Dr Lal Pathlabs to ’reduce rating with a price target of Rs 2,333, marking a 30 per cent downside. The stock fell almost 12 per cent for the day.",positive,negative,-0.9542372881355964,negative,3.230240549828179,positive
2021-04-18 20:25:03.000,2910.0,3044.0,2818.9,3004.0,1263186.0,"Dr Lal PathLabs shares show fatigue, following sharp rally",Valuations remain uncomfortably high with shares trading at 69 times estimated earnings for fiscal 2022,negative,positive,3.230240549828179,positive,-2.834952750787493,negative
2021-04-19 15:49:34.000,3000.05,3000.85,2861.0,2915.0,763437.0,"Market crash by over 1,200 points today: Jubilant Pharmova, Thyrocare, Dr Reddy, Pfizer, Dr Lal PathLabs among other healthcare stocks trade in green","After a decline of 1,257.56 points in the opening session, Sensex continued to be volatile. At 3 pm, it was down by 800 points, since the morning crash it has recovered by over 400 points. Meanwhile, Nifty in early trade was down by 379.10 points to 14,238.75.While the whole market is stru…",neutral,negative,-2.834952750787493,negative,-0.6542699724517906,neutral
2021-04-20 13:59:00.000,3000.05,3000.85,2861.0,2915.0,763437.0,"Tata Steel, Asian Paints among 21 stocks sending out weak signals on MACD charts","Data showed 21 stocks are showing bearish trends. They included Tata Steel, Biocon, Asian Paints, Dr Lal Pathlabs, Hindustan Unilever, Britannia Industries, Nestle India and Shree Cement.",neutral,negative,-2.834952750787493,negative,-0.6542699724517906,neutral
2021-04-20 20:29:00.000,3000.05,3000.85,2861.0,2915.0,763437.0,Near-term margin concerns and valuations weigh on Dr Lal Pathlabs,"Some brokerages prefer Metropolis given higher realisation, revenue growth trajectory",negative,neutral,-2.834952750787493,negative,-0.6542699724517906,neutral
2021-04-21 10:53:27.000,2904.0,2970.0,2871.6,2885.0,483396.0,Foreign Brokerages Raise Target Price Of These 6 Stocks; Do You Own Any?,"ACC, TCS, Mindtree and Dr Lal PathLabs are among the six stocks in which foreign brokerage houses raised the target price.",neutral,positive,-0.6542699724517906,neutral,-0.4004695159842543,neutral
2021-04-22 16:45:00.000,2896.6,2928.3,2805.0,2885.0,673829.0,CRISIL assigns AA- rating on Dr Lal Pathlabs’ long-term bank facilities; Stock up 1%,The outlook is Stable. The credit rating agency also assigned a short-term rating of CRISIL A1+ on the company’s bank loan facilities.,neutral,neutral,-0.4004695159842543,neutral,-2.0351845463953087,negative
2021-05-17 08:34:15.000,2690.0,2785.0,2632.05,2746.65,568195.0,"Stock picks by Sameet Chavan: Buy ITC, sell Dr Lal PathLabs",Dr Lal PathLabs’ stock seems to have lost its sheen now as we are seeing consistent corrective moves over the past few weeks,neutral,negative,2.105947955390338,positive,1.222776933651696,positive
2021-05-21 08:13:05.000,2898.25,2898.25,2800.0,2826.0,480081.0,"Stocks to Watch: SBI, Axis Bank, Mindtree, ICICI Bank, Havells, JSW Steel","Key companies that will announce their March quarter earnings are Hindalco Industries, JSW Steel, State Bank of India, Shree Cement, Crompton Greaves Consumer Electricals, Godrej Industries, Dr. Lal PathLabs, and Shoppers Stop",neutral,neutral,-2.492883636677305,negative,1.2727272727272727,positive
2021-05-21 08:21:00.000,2898.25,2898.25,2800.0,2826.0,480081.0,"Stocks in the news: SBI, RIL, NBCC, Apollo Tyres, IEX, Mindtree, Hindalco and Shree Cements","United Spirits, Dr Lal Pathlabs, Godrej Industries, Ircon International and Birlasoft are among companies which will announce their March quarter results today.",neutral,neutral,-2.492883636677305,negative,1.2727272727272727,positive
2021-05-21 08:36:00.000,2898.25,2898.25,2800.0,2826.0,480081.0,SGX Nifty up 130 points; here’s what changed for market while you were sleeping,"SBI, JSW Steel, Shree Cements, Hindalco Industries, United Spirits, Container Corporation of India, Crompton Greaves Consumer, Dr Lal Pathlabs, Godrej Industries, Ircon International and Birlasoft are among companies which will announce their March quarter results today.",neutral,neutral,-2.492883636677305,negative,1.2727272727272727,positive
2021-05-21 20:08:00.000,2898.25,2898.25,2800.0,2826.0,480081.0,Dr Lal PathLabs Q4 results: Net profit jumps over 2.5 times to Rs 85 cr,Its consolidated revenue from operations stood at Rs 431 crore for the quarter under consideration. It was Rs 301.7 crore for the same period a year ago.,positive,neutral,-2.492883636677305,negative,1.2727272727272727,positive
2021-05-21 21:21:45.000,2898.25,2898.25,2800.0,2826.0,480081.0,Results: Dr Lal PathLabs Q4 net profit jumps over 2.5 times to Rs 85.1 crore,"Diagnostics firm Dr Lal PathLabs on Friday reported an over 2.5 times rise in its consolidated net profit to Rs 85.1 crore for the quarter ended March 31, 2021, mainly on account of a rise in the non-COVID-19 business.The company had posted a net profit of Rs 32.6 crore for the correspondi…",positive,positive,-2.492883636677305,negative,1.2727272727272727,positive
2021-05-21 22:15:34.000,2898.25,2898.25,2800.0,2826.0,480081.0,Dr Lal PathLabs Q4 Net Profit Jumps Over 2.5 Times To Rs 85.1 Crore,"The company had posted a net profit of Rs 32.6 crore for the corresponding period of the previous financial year, Dr Lal PathLabs said in a regulatory filing.",neutral,positive,-2.492883636677305,negative,1.2727272727272727,positive
2021-05-24 00:37:12.000,2750.0,2809.7,2740.0,2785.0,498077.0,"Stocks to watch: SBI, JSW Steel, Sun Pharma, Hindalco, Reliance, Dr Lal PathLabs, Shriram Life, Godrej Industries among others","Steel companies’ stocks may see an impact of a letter written by industry body Indian Pipe Manufacturers’ Association (IPMA) to the government. It is seeking government intervention to regulate the prices of steel, which are trading at an all-time high in India. In a letter to Union Steel Ministe…",neutral,neutral,1.2727272727272727,positive,-0.733583825371265,neutral
2021-05-24 09:31:01.000,2750.0,2809.7,2740.0,2785.0,498077.0,Dr. Lal Pathlabs Q4 Review - Industry Leading Performance Continues: ICICI Securities,Dr. Lal Pathlabs Q4 Review - Industry Leading Performance Continues: ICICI Securities,neutral,neutral,1.2727272727272727,positive,-0.733583825371265,neutral
2021-05-25 11:45:19.000,2794.5,2816.4,2752.0,2774.0,210440.0,"For Dr Lal PathLabs, rising non-covid revenues, expansion aid growth","Near-term weakness in the non-covid portfolio is expected to be offset by the spurt in covid and covid-associated test volumes with adequate testing capacity and further scaling up the testing bandwidth, say analysts at JM Financials",positive,positive,-0.733583825371265,neutral,0.6022141285925597,neutral
2021-06-08 11:33:31.000,2989.0,3034.95,2930.05,2990.0,599050.0,Diagnostic services provider shares dip amid falling covid cases,"Metropolis Healthcare down 4%, Dr Lal Pathlabs, Thyrocare Technologies down nearly 2%",negative,negative,0.0334560053529608,neutral,-0.2362021357995911,neutral
2021-06-10 07:19:53.000,3000.0,3233.95,3000.0,3194.0,1873726.0,"Hot Stocks | Here’s Why Escorts, RIL, Dr Lal PathLabs Are Buy Calls For The Short Term","Support for Nifty is placed near 15,400–15,350 levels while resistance is near 15,800.",neutral,neutral,6.466666666666667,positive,0.0623052959501557,neutral
2021-06-17 19:36:00.000,3143.5,3291.95,3110.0,3160.0,1228543.0,"Exclusive: Suburban Diagnostics in sale talks with Dr Lal Pathlabs, Metropolis, PharmEasy, others","Mumbai-based Suburban Diagnostics, backed by Sequoia Capital, is said to have received bids ranging from Rs 800 crore to Rs 1,200 crore from Dr Lal Pathlabs and Metrolis for the buyout. Online pharmacy PharmEasy has also evinced interest.",neutral,positive,0.5248926355972642,neutral,0.8867623604465767,neutral
2021-07-30 14:15:00.000,3755.0,4050.0,3452.15,3559.0,2172755.0,Dr Lal Pathlabs consolidated net profit rises 361.97% in the June 2021 quarter,Sales rise 128.05% to Rs 606.60 crore,positive,positive,-5.219707057256991,negative,3.573422668900056,positive
2021-07-30 15:19:14.000,3755.0,4050.0,3452.15,3559.0,2172755.0,Dr Lal PathLabs Q1 net profit zooms nearly 5-fold to Rs 133.7 cr,"Diagnostic services provider Dr Lal PathLabs on Friday reported a nearly five-fold jump in consolidated net profit to Rs 133.7 crore for the quarter ended June 30, mainly on account of robust business growth. The company had posted a net profit of Rs 28.4 crore for the corresponding period…",positive,positive,-5.219707057256991,negative,3.573422668900056,positive
2021-07-30 17:05:08.000,3755.0,4050.0,3452.15,3559.0,2172755.0,Dr Lal PathLabs Q1 Net Profit Zooms Nearly 5-fold To Rs 133.7 Crore,"The company had posted a net profit of Rs 28.4 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a regulatory filing.",neutral,positive,-5.219707057256991,negative,3.573422668900056,positive
2021-08-02 17:31:00.000,3720.0,3943.75,3690.1,3900.0,1033757.0,Dr. Lal PathLabs resumes uptrend; adds over 61% this year,"Dr. Lal PathLabs surged 4.54% to end at Rs 3716, as the scrip resumed its uptrend after a day’s pause.",positive,positive,4.838709677419355,positive,-1.5128205128205128,negative
2021-08-05 07:28:00.000,3878.4,3995.0,3851.0,3971.05,951056.0,Diagnostic chains eye IPO route to raise funds,"The euphoria is aided by a massive spike in the share prices of already listed entities such as Metropolis Healthcare, Dr Lal Pathlabs, Medinova Diagnostics and Thyrocare.",neutral,positive,2.388871699669969,positive,-0.3318083555376758,neutral
2021-08-06 00:31:04.000,3978.2,4014.0,3924.75,3965.0,490996.0,"Analyst Corner: ‘Hold’ on Dr Lal Pathlabs with DCF-based target price of Rs 3,405","However, considering recent rally in the stock price which has made valuations fair, we downgrade it to HOLD from Add.",neutral,negative,-0.3318083555376758,neutral,-1.0419313850063534,negative
2021-08-10 08:11:05.000,3909.65,3930.0,3823.65,3880.7,212630.0,"Analyst Corner| Dr Lal Pathlabs: Downgrade to ‘hold’ with TP of Rs 3,405","Base business revenues grew 84.1% YoY, two year CAGR of 7.4% to Rs 3.8billion vs estimated Rs 4.1billion.",neutral,positive,-0.7404754901333949,neutral,-2.550359666106754,negative
2021-08-19 09:27:03.000,3982.0,4040.0,3834.4,3848.0,403835.0,Trade Spotlight: What Should Investors Do With Dr Lal Pathlabs & MindTree?,Dr Lal Pathlabs that rose 4 percent and MindTree gained around 6 percent on August 18 to hit a fresh 52-week high,neutral,positive,-3.3651431441486688,negative,-1.6368128474366872,negative
2021-09-01 09:38:00.000,4051.55,4238.0,4047.15,4174.8,561657.0,Should you still invest in Vijaya IPO despite Krsnaa’s poor show?,"At the upper end of the price band, the IPO is valued at 64 times FY21 earnings, which is at a 15-40 per cent discount to bigger peers Metropolis and Dr Lal PathLabs. When considered Vijaya’s annualised earnings for FY22, it is priced at 41 times, said Vikash Jain of Reliance Securities, who said th…",neutral,positive,3.042045636855031,positive,-1.455499880696731,negative
2021-09-13 11:43:33.000,4115.0,4182.0,4092.8,4155.9,185859.0,Dr Lal PathLabs sees firm investor confidence driven by growth opportunities,"Dr Lal is a debt-free, cash surplus company and has maintained a three-pronged strategy for capital utilisation. Dividend payouts and investments in the business, such as in technology, new machines/instruments, and expanding lab network, have remained key strategies",positive,positive,0.9939246658566132,positive,-0.7780934911100678,neutral
2021-10-06 17:39:08.000,3760.0,3783.2,3674.05,3689.2,200863.0,Dr. Lal PathLabs Q2 PAT Seen Up 28.4% YoY To Rs 112 Cr: Prabhudas Lilladher,"Net Sales are expected to increase by 26.8 percent Y-o-Y (down 9.7 percent Q-o-Q) to Rs 547.6 crore, according to Prabhudas Lilladher.",neutral,positive,-1.88297872340426,negative,-0.8696822832525628,neutral
2021-10-14 21:00:00.000,3780.0,3780.0,3675.0,3688.0,187309.0,Colorcon buys TA-backed pharma firm Ideal Cures,"​​TA Associates, which has invested in more than 500 companies around the globe, has a wide exposure in India with investments such as Indira IVF, Dr Lal Pathlabs, OmniActive and TCNS Clothing which sells W brand.",neutral,neutral,-2.433862433862434,negative,-2.5946647206681264,negative
2021-10-26 07:56:18.000,3493.55,3579.0,3416.05,3561.0,203846.0,"Stocks to Watch: Axis Bank, Bajaj Finance, BPCL, Airtel","Axis Bank, Kotak Mahindra Bank, Bajaj Finance, ABB India, Cipla, Ambuja Cements, Canara Bank, Central Bank of India, Dr Lal PathLabs, Mahanagar Gas, Persistent Systems, Torrent Pharmaceuticals, among others, will release their September quarter earnings today",neutral,neutral,1.930700863018987,positive,-1.974825174825172,negative
2021-10-26 08:18:55.000,3493.55,3579.0,3416.05,3561.0,203846.0,"Stock markets likely to consolidate; telcos, Eicher Motors, Axis Bank in focus","Among key companies, Bajaj Finance, Kotak Mahindra Bank, Axis Bank, Ambuja Cement, Cipla, Torrent Pharma, Canara Bank, Dr Lal Pathlabs, Nippon Life India Asset Management and Central Bank of India will announce their September quarter results today",positive,neutral,1.930700863018987,positive,-1.974825174825172,negative
2021-10-26 18:30:00.000,3575.0,3692.8,3451.1,3504.4,412540.0,Dr Lal Pathlabs consolidated net profit rises 11.37% in the September 2021 quarter,Sales rise 15.40% to Rs 498.40 crore,positive,positive,-1.974825174825172,negative,-0.1352150764810327,neutral
2021-10-26 21:37:00.000,3575.0,3692.8,3451.1,3504.4,412540.0,Dr Lal PathLabs Q2 net up 11 pc at Rs 96 cr; to acquire Suburban Diagnostics,Diagnostic services provider Dr Lal PathLabs on Tuesday posted a 10.6 per cent increase in its consolidated profit after tax (PAT) at Rs 96.3 crore for the second quarter ended September 30. The company had reported a PAT of Rs 87.1 crore in July-September in the year-ago period.,neutral,positive,-1.974825174825172,negative,-0.1352150764810327,neutral
2021-10-26 22:35:00.000,3575.0,3692.8,3451.1,3504.4,412540.0,Dr Lal PathLabs Q2 net up 11% at Rs 96 cr; to acquire Suburban Diagnostics,Diagnostic services provider Dr Lal PathLabs on Tuesday posted a 10.6 per cent increase in its consolidated profit after tax (PAT) at Rs 96.3 crore for the second quarter ended September 30,positive,positive,-1.974825174825172,negative,-0.1352150764810327,neutral
2021-10-27 09:53:00.000,3575.0,3692.8,3451.1,3504.4,412540.0,Dr. Lal PathLabs records revenue of Rs498.4cr in Q2 FY22,Net margins at 19.06% was lower than 19.75% on a yoy basis and it was sharply lower than NPM of 21.63% in Jun-21 quarter.,neutral,negative,-1.974825174825172,negative,-0.1352150764810327,neutral
2021-10-27 12:38:25.000,3549.9,3607.95,3481.0,3545.1,236223.0,Stocks that will see action today (October 27),"Buzzing stocks: IOB, PNB, Dr Lal PathLabs, IRB Infra, Nazara Tech, Firstsource, Maruti, Tata Chem, Titan, L&T, Adani Enterprises, Adani Power, RPower, Bajaj Auto",neutral,neutral,-0.1352150764810327,neutral,0.0070821529745042,neutral
2021-10-27 13:44:20.000,3549.9,3607.95,3481.0,3545.1,236223.0,Dr Lal PathLabs Q2 net profit up 10.6% at Rs 96 cr; to acquire Suburban Diagnostics,Dr Lal PathLabs Q2 net profit up 10.6% at Rs 96 cr; to acquire Suburban Diagnostics,positive,positive,-0.1352150764810327,neutral,0.0070821529745042,neutral
2021-10-27 17:30:00.000,3549.9,3607.95,3481.0,3545.1,236223.0,Dr Lal PathLabs acquires Suburban Diagnostics in an all-cash deal,Suburban Diagnostics founder Dr Sanjay Arora will join Dr Lal Pathlabs as Group Medical Director. The acquisition is expected to close in a month.,neutral,neutral,-0.1352150764810327,neutral,0.0070821529745042,neutral
2021-10-27 19:06:00.000,3549.9,3607.95,3481.0,3545.1,236223.0,We entered an otherwise hard market with Suburban deal: Dr Lal Pathlabs MD,"In a Q&A, Om Manchanda says the firm is now growing organically in the Southern market, but is open to inorganic opportunities there",neutral,neutral,-0.1352150764810327,neutral,0.0070821529745042,neutral
2021-10-28 13:41:10.000,3530.0,3579.5,3487.75,3530.25,115656.0,Dr. Lal Pathlabs Q2 Review - Suburban Acquisition Overshadows An Inline Quarter: Yes Securities,Dr. Lal Pathlabs Q2 Review - Suburban Acquisition Overshadows An Inline Quarter: Yes Securities,neutral,neutral,0.0070821529745042,neutral,4.561101549053356,positive
2021-11-30 09:07:30.000,3922.0,3923.4,3656.35,3797.0,819092.0,"Trade Spotlight | What Should You Do With Dr Lal PathLabs, PNB Housing Finance, Navin Fluorine, And HCL Technologies?","Here’s what Karan Pai of GEPL Capital, recommends investors should do with these stocks when the market resumes trading today.",neutral,neutral,-3.187149413564508,negative,-2.634533538734695,negative
2021-11-30 09:56:00.000,3922.0,3923.4,3656.35,3797.0,819092.0,Dr Lal PathLab corrects after four-day rally,Dr Lal PathLabs fell 5.23% to Rs 3683 on profit booking after soaring in the past four sessions.,neutral,negative,-3.187149413564508,negative,-2.634533538734695,negative
2021-11-30 10:16:30.000,3922.0,3923.4,3656.35,3797.0,819092.0,Dr Lal Pathlabs Ltd Falls 3.18%,Dr Lal Pathlabs Ltd has added 7.12% over last one month compared to 1.6% gain in S&P BSE Healthcare index and 2.45% drop in the SENSEX,neutral,positive,-3.187149413564508,negative,-2.634533538734695,negative
2021-12-01 07:25:46.000,3829.9,3837.5,3700.1,3729.0,237663.0,"Hot Stocks | Here’s Why You Should Bet On TCS, Dr Lal PathLabs, Max Healthcare Institute For Short Term",Shitij Gandhi of SMC Global Securities expects markets to remain under pressure in upcoming sessions as well and likely to trade on volatile path.,neutral,negative,-2.634533538734695,negative,1.0585106382978773,positive
2021-12-03 08:59:00.000,3835.0,3878.95,3658.0,3703.0,453246.0,"Buy Dr. Lal Pathlabs, target price Rs 4050: Yes Securities","Dr. Lal Pathlabs Ltd., incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 31613.13 Crore) operating in Hospitals & Allied Services sector.",neutral,neutral,-3.441981747066493,negative,-3.843074459567654,negative
2022-01-12 15:10:00.000,3699.0,3769.95,3673.8,3718.0,160236.0,Fortis Malar Hospitals appoints Chandrasekar Ramasamy as Whole Time Director and KMP,"He has over 21 years of work experience across companies like Sanofi, GSK Pharmaceuticals, Medtronic and Dr. Lal Pathlabs.",neutral,neutral,0.5136523384698567,neutral,-2.329136328894965,negative
2022-01-13 11:33:55.000,3699.0,3769.95,3673.8,3718.0,160236.0,LIC picks up stake in this healthcare stock in December quarter,"LIC has bought 1.12% stake in Dr Lal PathLabs during the October-December 2021 period, BSE data showed",neutral,neutral,0.5136523384698567,neutral,-2.329136328894965,negative
2022-01-13 17:00:30.000,3728.85,3729.0,3600.0,3642.0,119541.0,"LIC invests, mutual funds increase stake in THIS healthcare firm; have you invested?",LIC has invested in Dr Lal PathLabs in the quarter ending with December 2021.,neutral,neutral,-2.329136328894965,negative,-3.975870578557719,negative
2022-02-10 07:43:35.000,2974.0,2995.95,2895.6,2944.0,346645.0,"Stocks to Watch: Hero MotoCorp, Zomato, M&M, MRF, Hindalco","Shares of firms like Hero MotoCorp, Zomato, Mahindra & Mahindra, Mindspace Business Parks REIT, MRF, Reliance Power, Hindalco Industries, Page Industries, Cummins India, Bombay Dyeing, Gujarat Pipavav Port, HAL, Dr Lal PathLabs will be in focus as they will announce their Q3 results today",neutral,neutral,-1.0087424344317415,negative,-0.7360011188615647,neutral
2022-02-10 20:13:00.000,2860.05,2904.15,2802.0,2839.0,244642.0,Diagnostics chain Dr Lal PathLabs posts Rs 58 crore profit for Dec quarter,Diagnostics chain Dr Lal PathLabs Ltd on Thursday reported a consolidated net profit of Rs 58.2 crore in the third quarter ended in December 2021.,neutral,neutral,-0.7360011188615647,neutral,-3.597122302158273,negative
2022-02-11 11:49:41.000,2860.05,2904.15,2802.0,2839.0,244642.0,Dr Lal PathLabs’ Q3 performance hit by acquisition cost,"Analysts say the acquisition of Suburban Diagnostics was important from a long-term perspective of making Dr Lal PathLabs a pan-India company, and the company may prefer to gain scale over improving margins at this stage",negative,positive,-0.7360011188615647,neutral,-3.597122302158273,negative
2022-02-11 14:58:00.000,2860.05,2904.15,2802.0,2839.0,244642.0,Dr Lal PathLabs very confident of coming back to pre-Covid growth levels: CEO,"“Our long-term growth enablers for growth are all progressing well – be it technological interventions, network expansion strategy or capability building. All the long-term initiatives are going as per plan and we feel very confident of coming back to our pre-Covid growth levels as soon as the pande…",positive,positive,-0.7360011188615647,neutral,-3.597122302158273,negative
2022-02-11 17:30:00.000,2860.05,2904.15,2802.0,2839.0,244642.0,Dr Lal Pathlabs stock slips over 4% post weak Q3 earnings,"The share touched an intraday low of Rs 2,800.25, down 4.45% against the previous close of Rs 2,930 on BSE.",negative,negative,-0.7360011188615647,neutral,-3.597122302158273,negative
2022-03-09 21:31:00.000,2699.0,2699.0,2554.5,2605.0,332709.0,Ahead of Market: 12 things that will decide stock action on Thursday,"Momentum indicator Moving Average Convergence Divergence (MACD) showed bullish trade setup on the counters of IOL Chemicals, Dr Lal Pathlabs, Hemisphere Properties, Infibeam Avenues, Cummins India and Indiabulls Real Estate.",neutral,positive,-3.4827713968136345,negative,1.517220160375356,positive
2022-03-29 09:29:00.000,2575.0,2643.65,2557.0,2610.25,226244.0,Stock Price - Lal PathLabs’s stock price correction provides good entry point: Why it’s this week’s stock pick,"Dr Lal PathLabs is focused on cost optimisation measures and is following a low capital-intensive strategy. Its strong brand value, high return ratios, large network, cost efficiencies, etc. are the other factors that have made the company a favourite of analysts.",positive,neutral,1.3689320388349515,positive,-0.7774171635595276,neutral
2022-04-05 16:41:00.000,2785.0,2808.5,2681.0,2699.0,352554.0,Blood Samples : Dr Lal PathLabs to use drones for transporting blood samples,"The use of drones would expand Dr Lal PathLabs services of high-quality and advanced diagnostics to underserved and inaccessible locations, the company said.",neutral,positive,-3.087971274685817,negative,4.21883605654489,positive
2022-04-05 17:30:00.000,2785.0,2808.5,2681.0,2699.0,352554.0,Dr Lal PathLabs announces pilot project to transport blood samples via drones,"The company, in a statement, said that the use of drones would expand Dr Lal PathLab’s services of high-quality and advanced diagnostics to underserved and inaccessible locations.",positive,positive,-3.087971274685817,negative,4.21883605654489,positive
2022-04-05 19:25:00.000,2785.0,2808.5,2681.0,2699.0,352554.0,Dr Lal PathLabs unveils pilot project to transport blood samples via drones,The company is initiating pilot projects in different parts of the country,neutral,neutral,-3.087971274685817,negative,4.21883605654489,positive
2022-05-05 16:51:00.000,2437.0,2437.0,2358.75,2405.0,132032.0,Diagright to expand paramedic service to 200 cities; eyes Rs 50 cr business this fiscal,"COO of Diagright said the startup has over 32,000 phlebotomists and paramedics on its platform and partnered with over 1,500 labs including Dr. Lal pathlabs, Metropolis, Redcliffe etc. for providing services in about 37 cities across North India.",positive,neutral,-1.3130898645876077,negative,-0.6449579831932735,neutral
2022-05-06 18:31:52.000,2437.0,2437.0,2358.75,2405.0,132032.0,Dr Lal Pathlabs allots 7000 equity shares under ESOP,Powered by Capital Market - Live News,neutral,neutral,-1.3130898645876077,negative,-0.6449579831932735,neutral
2022-05-17 17:17:00.000,2095.0,2143.0,2017.6,2055.0,1607916.0,Dr Lal Pathlabs standalone net profit declines 17.15% in the March 2022 quarter,Sales rise 2.67% to Rs 414.90 crore,negative,positive,-1.909307875894988,negative,-4.6,negative
2022-05-17 17:34:00.000,2095.0,2143.0,2017.6,2055.0,1607916.0,Dr Lal Pathlabs consolidated net profit declines 26.50% in the March 2022 quarter,Sales rise 12.65% to Rs 485.50 crore,negative,positive,-1.909307875894988,negative,-4.6,negative
2022-05-17 19:34:00.000,2095.0,2143.0,2017.6,2055.0,1607916.0,"Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%",Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line,neutral,positive,-1.909307875894988,negative,-4.6,negative
2022-05-17 20:29:18.000,2095.0,2143.0,2017.6,2055.0,1607916.0,Dr Lal Pathlabs reports 27 per cent dip in Q4 profit,Operating revenue increases by 13 per cent to ₹486 crore,negative,positive,-1.909307875894988,negative,-4.6,negative
2022-05-18 09:46:05.000,2095.0,2143.0,2017.6,2055.0,1607916.0,Dr. Lal Pathlabs Q4 Review - Margin Woes May Not Be Structural: Yes Securities,Dr. Lal Pathlabs Q4 Review - Margin Woes May Not Be Structural: Yes Securities,neutral,neutral,-1.909307875894988,negative,-4.6,negative
2022-05-18 09:51:00.000,2095.0,2143.0,2017.6,2055.0,1607916.0,"Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results","In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 per cent in Q4FY21",negative,positive,-1.909307875894988,negative,-4.6,negative
2022-05-18 11:04:10.000,2095.0,2143.0,2017.6,2055.0,1607916.0,Volumes soar at Dr Lal Pathlabs Ltd counter,"Dr Lal Pathlabs Ltd recorded volume of 47020 shares by 10:47 IST on BSE, a 3.25 times surge over two-week average daily volume of 14470 shares",neutral,positive,-1.909307875894988,negative,-4.6,negative
2022-05-18 14:26:00.000,2000.0,2004.85,1903.05,1908.0,818634.0,"Metropolis, Dr Lal Pathlabs Tank to 52-Week Lows: Is It a Buying Opportunity?","Metropolis, Dr Lal Pathlabs Tank to 52-Week Lows: Is It a Buying Opportunity?",neutral,neutral,-4.6,negative,1.7090021297594975,positive
2022-05-18 15:04:05.000,2000.0,2004.85,1903.05,1908.0,818634.0,Metropolis Healthcare Ltd leads losers in ‘A’ group,"Acrysil Ltd, Dr Lal Pathlabs Ltd, Paushak Ltd and Delta Corp Ltd are among the other losers in the BSE’s ‘A’ group today, 18 May 2022.",positive,negative,-4.6,negative,1.7090021297594975,positive
2022-05-19 06:06:00.000,2000.0,2004.85,1903.05,1908.0,818634.0,"We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD","Dr Lal PathLabs is India’s largest diagnostic services player by revenue, with 289 laboratories across the country",neutral,neutral,-4.6,negative,1.7090021297594975,positive
2022-05-19 08:29:00.000,2000.0,2004.85,1903.05,1908.0,818634.0,"Big Movers on D-St: What should investors do with Dr Lal Pathlabs, Metropolis Healthcare and MRPL?","Stocks that were in focus include names like Dr Lal PathLabs, which was down more than 6 per cent, Metropolis Healthcare fell more than 9 per cent, and MRPL rose nearly 10 per cent.",neutral,neutral,-4.6,negative,1.7090021297594975,positive
2022-05-27 15:47:51.000,2034.5,2211.2,2002.0,2211.2,1497275.0,"Sensex Sprints 632 pts At Close, Nifty Above 16,350; Dr Lal Pathlabs Up 10%","The Sensex and Nifty opened in the green territory on Friday, tracking overnight strength in the US markets and firm Asian indices this morning",neutral,positive,8.685180634062414,positive,-6.533333333333332,negative
2022-05-29 10:28:06.000,2250.0,2250.1,2071.0,2103.0,913267.0,Movers & Shakers: 10 stocks that moved the most last week,"AstraZeneca Pharma, Dr Lal Pathlabs, Torrent Pharma, and InterGlobe Aviation among those who moved the most",neutral,neutral,-6.533333333333332,negative,-1.3267392648247702,negative
2022-05-30 08:45:00.000,2250.0,2250.1,2071.0,2103.0,913267.0,"Big Movers on D-St: What should investors do with Godrej Industries, Dr Lal PathLabs & Piramal Enterprises?","Stocks which remained in focus included names like Godrej Industries, which rallied more than 10 per cent, Dr Lal PathLabs which rose more than 9 per cent, and Piramal Enterprises which plunged over 11 per cent.",neutral,neutral,-6.533333333333332,negative,-1.3267392648247702,negative
2022-06-08 21:01:13.000,2125.0,2165.0,2080.65,2142.0,195611.0,Trade setup for Thursday: Top 15 things to know before Opening Bell,"Based on the open interest future percentage, a long build-up was seen in 30 stocks including TVS Motor Company, JK Cement, Dr Lal PathLabs, Dalmia Bharat, and Bandhan Bank",neutral,positive,0.8,neutral,-0.6175771971496438,neutral
2022-06-10 20:22:18.000,2105.0,2120.0,2060.1,2092.0,196822.0,‘Margins in diagnostics business set to return to pre-Covid levels’,"According to Om Manchanda of Dr Lal Pathlabs, disruptive pricing is not sustainable in the diagnostics business",positive,negative,-0.6175771971496438,neutral,0.6796116504854369,neutral
2022-07-20 09:01:00.000,2051.0,2108.75,2036.0,2094.0,303727.0,"What Bajaj Finance did in 2020, can Dr Lal Pathlabs do in 2022? Saurabh Mukherjee answers","“In late April 2020, we almost doubled up our position in Bajaj Finance and that worked out for us. So this time around, we have loaded up heavily on Dr Lal Path Labs which has had a correction very similar to what Bajaj had in that run up to the initial Covid panic. Bajaj almost halved. Similarly,…",neutral,positive,2.096538274012677,positive,-0.2229601518026479,neutral
2022-07-28 16:03:00.000,2140.0,2343.7,2127.6,2302.0,699111.0,Dr Lal PathLabs Q1 Results: Net profit dips 57% to Rs 58 crore,"The company had reported a net profit of Rs 134 crore in the April-June period of the last fiscal.Revenue from operations declined to Rs 503 crore in the period under review from Rs 607 crore a year ago, Dr Lal PathLabs said in a regulatory filing.",negative,negative,7.570093457943925,positive,-0.129366106080207,neutral
2022-07-28 16:11:31.000,2140.0,2343.7,2127.6,2302.0,699111.0,Dr Lal PathLabs Q1 net profit dips 57 per cent to ₹58 cr,Dr Lal PathLabs board has declared an interim dividend of ₹6 per share for the current fiscal,negative,neutral,7.570093457943925,positive,-0.129366106080207,neutral
2022-07-28 16:47:22.000,2140.0,2343.7,2127.6,2302.0,699111.0,Dr Lal PathLabs Q1 net profit dips 57% to Rs 58 cr; revenue falls 17%,Diagnostic services provider Dr Lal Path Labs on Thursday said its consolidated net profit declined 57 per cent to Rs 58 crore for the first quarter ended June 30,negative,negative,7.570093457943925,positive,-0.129366106080207,neutral
2022-07-29 13:26:30.000,2140.0,2343.7,2127.6,2302.0,699111.0,"We are focussed on productivity, says Dr Lal PathLabs MD","On the firm’s Q1FY23 numbers, Om Manchanda said the diagnostics chain’s legacy business was up 15% YoY",neutral,positive,7.570093457943925,positive,-0.129366106080207,neutral
2022-08-31 00:27:00.000,2540.0,2559.9,2460.35,2479.05,166431.0,Dr Lal PathLabs pulls up its socks as competition mounts,"Gurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, competition intensifying with the entry of e-pharmacies, web aggregators and pharma companies into diagnostics, resulting in a price war at a time when inflation…",neutral,negative,-2.399606299212591,negative,-1.8409366168752488,negative
2022-08-31 08:34:00.000,2540.0,2559.9,2460.35,2479.05,166431.0,Dr Lal pulls up its socks as competition mounts,"Gurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, competition intensifying with the entry of e-pharmacies, web aggregators and pharma companies into diagnostics, resulting in a price war at a time when inflation…",neutral,negative,-2.399606299212591,negative,-1.8409366168752488,negative
2022-09-29 07:12:57.000,2716.9,2718.0,2560.0,2583.3,433513.0,"Trade Spotlight | What should you do with India Cements, Dr Lal PathLabs, Glenmark Pharma on Thursday?","Dr Lal PathLabs shares gained 1.7 percent to Rs 2,694.35, continuing uptrend for the seventh consecutive session. It has seen formation of bullish candle on the daily charts with higher high higher low formation for seven straight sessions, and has given a breakout of downward sloping resistance tre…",neutral,positive,-4.917369060326104,negative,-2.6781907677996943,negative
2022-09-29 15:16:52.000,2580.1,2610.0,2508.35,2511.0,256816.0,Aarti Industries Ltd leads losers in ‘A’ group,"Asian Paints Ltd, JSW Holdings Ltd, Intellect Design Arena Ltd and Dr Lal Pathlabs Ltd are among the other losers in the BSE’s ‘A’ group today, 29 September 2022.",negative,negative,-2.6781907677996943,negative,-5.294585987261147,negative
2022-09-29 20:49:38.000,2580.1,2610.0,2508.35,2511.0,256816.0,Why Dr Lal PathLabs’ November futures trade in deep discount?,Price behaviour puzzles analysts as ‘It defies any logic’,neutral,neutral,-2.6781907677996943,negative,-5.294585987261147,negative
2022-10-10 09:05:00.000,2415.0,2429.35,2365.3,2374.0,233186.0,Festive cheer to boost demand; Dr Lal Pathlabs among top 3 stocks to give 13-16% return: Mohit Nigam,The Nifty50 is expected to face short-term turbulence as investors have become cautious of further aggressive rate hikes by the US Fed after the release of US Job data last Friday.,positive,negative,-1.6977225672877845,negative,-4.23728813559322,negative
2022-10-24 17:30:00.000,2576.5,2635.0,2565.35,2622.0,274706.0,"Diagnostics is the next big battleground: How Dr Lal Pathlabs, SRL are trying to hold fort","The diagnostics majors are looking at inorganic growth for their network expansion which is further heightening the competition. For instance, Dr Lal PathLabs acquired Suburban Diagnostics in 2021 for Rs 925 crore in West India. It is also planning expansion in South India.",neutral,positive,1.7659615757810985,positive,-0.7628359997717095,neutral
2022-10-24 17:30:00.000,2576.5,2635.0,2565.35,2622.0,274706.0,"Diagnostics is the next battleground: How Dr Lal Pathlabs, SRL are trying to hold fort","The diagnostics majors are looking at inorganic growth for their network expansion which is further heightening the competition. For instance, Dr Lal PathLabs acquired Suburban Diagnostics in 2021 for Rs 925 crore in West India. It is also planning expansion in South India.",neutral,positive,1.7659615757810985,positive,-0.7628359997717095,neutral
2022-11-08 21:37:15.000,2550.0,2574.5,2391.0,2407.0,839087.0,"Dr Lal PathLabs Q2 profit slumps on falling Covid income, higher expenses",Indian medical diagnostics firm Dr. Lal PathLabs Ltd on reported a 24.5% drop in September quarter profit as a sustained decline in revenue and volume from its Covid-19 related business,negative,negative,-5.607843137254902,negative,-1.100464454579697,negative
2022-11-09 10:50:57.000,2550.0,2574.5,2391.0,2407.0,839087.0,Dr. Lal PathLabs slumps as Q2 PAT slides 24% YoY,"Dr. Lal PathLabs tumbled 7.79% to Rs 2,421.15 after the healthcare service provider’s consolidated net profit slipped 24.53% to Rs 71.7 crore despite of 7.1% rise in revenue from operations to Rs 533.8 crore in Q2 FY23 over Q2 FY22.",neutral,negative,-5.607843137254902,negative,-1.100464454579697,negative
2022-11-09 17:30:00.000,2389.9,2397.55,2316.05,2363.6,433128.0,"Dr Lal PathLabs shares dive 8% after Q2 results. Should you hold, sell, or buy?","Dr Lal PathLabs share price: Considering the previous closing, New Delhi-based Dr Lal PathLabs traded more than 45 per cent higher from its May low of Rs 1,805.10 and 33 per cent lower from its 52-week high of Rs 3,943.95, touched in November last year.",positive,positive,-1.100464454579697,negative,-1.3198823034888647,negative
2022-11-09 23:08:16.000,2389.9,2397.55,2316.05,2363.6,433128.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the open interest future percentage, there were 84 stocks in which a short build-up was seen including Jubilant FoodWorks, MRF, Dr Lal PathLabs, Ramco Cements, and Divi’s Laboratories.",neutral,neutral,-1.100464454579697,negative,-1.3198823034888647,negative
2022-11-24 12:54:17.000,2393.0,2439.65,2370.1,2426.2,133805.0,US-based Wasatch Advisors buys stakes in Dr Lal PathLabs taking total to 7.04%,US-based Wasatch Advisors Inc on Monday bought 2 per cent stakes in Dr. Lal PatLabs Limited.,neutral,neutral,1.3873798579189225,positive,-0.6111817547889614,neutral
2022-11-29 22:21:55.000,2406.0,2475.0,2404.95,2438.05,209683.0,Trade setup for Wednesday: Top 15 things to know before the opening bell,"Based on the open interest future percentage, a short build-up was seen in 69 stocks, including Laurus Labs, ABB India, Shriram Transport Finance, Coal India and Dr Lal PathLabs",neutral,positive,1.3320864505403236,positive,-0.7307144311011528,neutral
2022-12-13 17:30:00.000,2379.0,2428.95,2357.8,2380.95,240387.0,"What analysts say on Bharat Dalmia, Paytm, SBI Card, HUL and Dr Lal Pathlabs","For Paytm, foreign brokerage Morgan Stanley said GMV growth remained healthy, though it moderated on a YoY basis vis-à-vis last month. Average MTU, it said, was steady and growth sustained at 32 per cent YoY",neutral,positive,0.0819672131147464,neutral,-0.631578947368421,neutral
2022-12-13 22:56:08.000,2379.0,2428.95,2357.8,2380.95,240387.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the open interest future percentage, we saw short build-up in total 58 stocks on Tuesday that included Dr Lal PathLabs, Laurus Labs, Metropolis Healthcare, Can Fin Homes, and BPCL.",neutral,positive,0.0819672131147464,neutral,-0.631578947368421,neutral
2022-12-21 10:11:54.000,2334.9,2440.0,2310.9,2435.0,1778606.0,"Diagnostic firm shares Dr Lal PathLabs, Metropolis surge on China covid concern",The Indian government on Tuesday urged all states and union territories to ramp up the whole genome sequencing of positive samples to keep track of newer covid variants.,neutral,positive,4.287121504132935,positive,-3.5089869281045787,negative
2022-12-21 15:37:21.000,2448.0,2459.35,2325.55,2362.1,598309.0,"Healthcare Stocks Surge on Renewed Covid Fears; Dr Lal PathLabs, Cipla Rise Up to 6%",Healthcare Stocks Rise: Shares of healthcare service providers jumped on Wednesday amid renewed fears of Covid outbreaks,neutral,positive,-3.5089869281045787,negative,-1.0575296108291032,negative
2023-01-09 00:09:00.000,2231.95,2269.0,2214.8,2230.0,185625.0,Dr Lal PathLabs to ramp up operations in Western India,"“The new reference lab provides a wide array of super-specialised, specialised and routine diagnostic tests for meeting all diagnostic needs,” said Dr Arvind Lal, chairman of Dr Lal Pathlabs.",positive,neutral,-0.0873675485561871,neutral,-0.2662251951945152,neutral
2023-01-09 08:52:44.000,2231.95,2269.0,2214.8,2230.0,185625.0,"Stocks to Watch Today: TCS, Paytm, IDBI Bank, Lupin, Dr Lal PathLabs, and Others","Stocks to watch: Shares of firms like TCS, Paytm, IDBI Bank, Lupin, Dr Lal PathLabs, and others will be in focus in Monday’s trade.",neutral,neutral,-0.0873675485561871,neutral,-0.2662251951945152,neutral
2023-01-09 13:05:13.000,2234.95,2253.5,2218.35,2229.0,105453.0,Lal PathLabs targets leadership position in west India in 5 years,"Om Manchanda, MD, Dr Lal Pathlabs said that the contribution of the west zone has gone up from 6 percent in FY15 to 8 percent in FY20 and 15 percent in the first half of FY23",positive,positive,-0.2662251951945152,neutral,-2.778087693852505,negative
2023-01-11 10:50:14.000,2240.75,2247.95,2175.0,2178.5,164273.0,CARE Ratings assigns “AA” rating to Dr. Lal PathLabs,Dr. Lal PathLabs said that CARE Ratings has assigned “CARE AA” rating with ‘stable’ outlook to the long-term bank facilities of the company worth Rs 229 crore.,neutral,positive,-2.778087693852505,negative,-1.0605542251111872,negative
2023-02-02 15:43:06.000,2006.0,2017.7,1878.95,1888.0,420409.0,Dr Lal PathLabs Q3 net profit falls 7% to ₹54 crore,"Shares of the company were trading 1.63 per cent down at ₹2,019.15 apiece on the BSE",negative,negative,-5.88235294117647,negative,4.339292345233684,positive
2023-02-02 15:48:03.000,2006.0,2017.7,1878.95,1888.0,420409.0,Dr Lal PathLabs Q3 net profit falls 7% to Rs 54 crore,"Shares of the company were trading 1.63 percent down at Rs 2,019.15 apiece on the BSE.",negative,negative,-5.88235294117647,negative,4.339292345233684,positive
2023-02-02 15:54:47.000,2006.0,2017.7,1878.95,1888.0,420409.0,"Dr Lal PathLabs Q3 net down 7% to Rs 54 cr, revenue declines to Rs 489 cr",Dr Lal PathLabs on Thursday said its consolidated profit after tax declined 7 per cent to Rs 54 crore for the December quarter.,negative,negative,-5.88235294117647,negative,4.339292345233684,positive
2023-02-14 22:25:56.000,1979.35,1990.0,1957.05,1960.0,79345.0,Trade setup for today: Top 15 things to know before the opening bell,"Based on the OI percentage, 52 stocks, including ITC, Polycab India, Metropolis Healthcare, Dr Lal PathLabs, and Marico, saw a long build-up on February 14.",neutral,positive,-0.9775936544825276,negative,1.7234795448181124,positive
2023-03-03 12:25:00.000,1981.0,1990.75,1952.05,1954.05,116709.0,"Looking at strengthening current core offerings & building consumer trust: Bharath Uppiliappan, Dr. Lal PathLabs","I guess the industry has now kind of come back to realising that it is good to be back on the basics front and hence a lot of things which we used to talk about is really coming back to what we would do in the normal pre-COVID days which is really looking about expansion, which is looking at strengt…",positive,neutral,-1.3604240282685536,negative,-0.2524286697774061,neutral
2023-03-21 11:17:00.000,1798.65,1810.25,1773.1,1781.95,155960.0,"Buy Dr. Lal Pathlabs, target price Rs 2620: JM Financial","Dr. Lal Pathlabs, incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 15012.92 Crore) operating in Hospitals & Allied Services sector.",neutral,neutral,-0.9284741333778136,negative,2.2408963585434174,positive
2023-05-11 14:49:06.000,1910.0,2059.0,1892.2,2059.0,772319.0,Dr Lal PathLabs Q4 result: Net profit falls 7.5% to Rs 57 crore,"Dr Lal PathLabs Q4 result: On the operating front, earnings before interest, taxes, depreciation and amortization) decreased by 4.5 percent to Rs 115.6 crore",negative,negative,7.801047120418849,positive,-0.6432459178624443,neutral
2023-05-11 15:15:09.000,1910.0,2059.0,1892.2,2059.0,772319.0,Dr Lal PathLabs reports decline in profit for quarter ending March,Dr. Lal PathLabs Ltd on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from Covid-related testing outpaced growth in its core business,negative,negative,7.801047120418849,positive,-0.6432459178624443,neutral
2023-05-11 17:19:59.000,1910.0,2059.0,1892.2,2059.0,772319.0,Dr Lal PathLabs Q4 net profit falls 8 pc to Rs 57 crore | The Financial Express,"Dr Lal PathLabs on Thursday said its consolidated profit after tax declined 8 per cent to Rs 57 crore for the fourth quarter ended March 31, 2023.",negative,negative,7.801047120418849,positive,-0.6432459178624443,neutral
2023-05-11 17:49:30.000,1910.0,2059.0,1892.2,2059.0,772319.0,Dr Lal PathLabs Q4 net profit falls 8% to Rs 57 crore,"Revenue from operations rose to Rs 491 crore for the fourth quarter as compared with Rs 485 crore in the year-ago period, Dr Lal PathLabs said in a regulatory filing.",negative,positive,7.801047120418849,positive,-0.6432459178624443,neutral
2023-05-12 09:33:52.000,1910.0,2059.0,1892.2,2059.0,772319.0,Dr Lal PathLabs stock under pressure after March quarter earnings fails to impress,Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago.,negative,negative,7.801047120418849,positive,-0.6432459178624443,neutral
2023-05-12 09:46:17.000,1910.0,2059.0,1892.2,2059.0,772319.0,Dr. Lal Pathlabs Q4 Results Review - Caution Warranted On Volume Growth: Yes Securities,"Excluding Suburban, implied non Covid sales up 7.5% YoY on what was a weak base of Rs 4.2 billion last year",neutral,positive,7.801047120418849,positive,-0.6432459178624443,neutral
2023-05-12 11:06:00.000,1910.0,2059.0,1892.2,2059.0,772319.0,"We continue to invest in building labs, infrastructure to have sustainable growth profile: Bharath Uppiliappan, Dr Lal Pathlabs","Now you would remember that in FY21-22 we had the Omicron and the Delta wave coming in. So, what you are seeing this year as a minus 5% is really not minus 5. It is a total patient because of large COVID base of the previous year",positive,neutral,7.801047120418849,positive,-0.6432459178624443,neutral
2023-05-15 09:56:00.000,2021.0,2078.0,2001.0,2008.0,470204.0,"Hot Stocks: Brokerages on HPCL, Manappuram Finance, Dr Lal Pathlabs and Lupin",Jefferies maintained an underperform rating on Hindustan Petroleum Corporation Limited (HPCL) citing weak marketing and transitory refining weakness. CLSA retained a buy rating on Manappuram Finance as yields fell but growth became visible. Credit Suisse upheld an underperform rating on Dr Lal Pathl…,neutral,positive,-0.6432459178624443,neutral,0.7451564828614009,neutral
2023-05-24 23:09:25.000,2035.0,2057.0,2018.8,2024.1,108019.0,Trade setup for Thursday: Top 15 things to know before the opening bell,"Based on the OI percentage, 60 stocks were on the short-covering list. These included Alkem Laboratories, IndusInd Bank, United Breweries, Dr Lal PathLabs and Aarti Industries.",neutral,neutral,-0.5356265356265401,neutral,0.0,neutral
2023-06-15 23:17:02.000,1994.0,2035.0,1992.5,2035.0,527924.0,Trade setup for Friday: Top 15 things to know before the opening bell,"Based on the OI percentage, 63 stocks including Tata Chemicals, Dr Lal PathLabs, Wipro, Federal Bank and State Bank of India saw a short build-up.",neutral,neutral,2.056168505516549,positive,3.560975609756097,positive
2023-06-18 18:35:36.000,2050.0,2142.4,2040.4,2123.0,1264245.0,Trade setup for Monday: Top 15 things to know before the opening bell,"Based on the OI percentage, 87 stocks including Oracle Financial, Dr Lal PathLabs, LTIMindtree, Metropolis Healthcare, and Ashok Leyland saw a long build-up.",neutral,neutral,3.560975609756097,positive,4.029990627928772,positive
2023-06-25 18:43:12.000,2109.85,2184.95,2075.55,2170.0,382166.0,Trade setup for Monday: Top 15 things to know before the opening bell,"Based on the OI percentage, a short build-up was seen in 90 stocks including Dr Lal PathLabs, Hindustan Aeronautics, Ramco Cements, MCX India, and Mahanagar Gas.",neutral,positive,2.85091357205489,positive,1.6996518233461564,positive
2023-06-26 21:47:09.000,2182.8,2229.45,2165.0,2219.9,467339.0,Trade setup for Tuesday: Top 15 things to know before the opening bell,"As many as 88 stocks were on the short-covering list based on the open interest percentage. These included Rain Industries, Hindustan Aeronautics, Dr Lal PathLabs, LIC Housing Finance and Mahanagar Gas",neutral,neutral,1.6996518233461564,positive,-0.7631869245142763,neutral
2023-06-29 14:16:32.000,2209.9,2290.0,2206.1,2259.0,415497.0,"Dr Lal PathLabs, Metropolis and Thyrocare: Why shares underperformed last year and should you buy now?","The companies themselves are trading at a higher valuation of 57 times FY24 earnings for Dr Lal PathLabs, 47 times, and 29 times for Metropolis and Thyrocare respectively",negative,positive,2.2218199918548307,positive,-0.3041121248181978,neutral
2023-07-27 05:00:00.000,2429.95,2499.0,2415.0,2494.0,595453.0,"Nestle India, Indian Hotels, ACC, Dr Lal Pathlabs Q1 Results Today — Earnings Estimates",Here are the estimates of the major companies that are scheduled to announce their results on Thursday.,neutral,neutral,2.6358567048704784,positive,-6.466484926234772,negative
2023-07-27 14:46:16.000,2494.4,2494.4,2325.0,2333.1,746549.0,"Dr Lal PathLabs Q1 Results: Profit Rises 43%, Beats Estimates",Dr Lal PathLabs’ Q1 revenue rose 8% to Rs 541 crore as against an estimate of Rs 548 crore.,neutral,positive,-6.466484926234772,negative,-1.5718801043677555,negative
2023-07-31 11:55:04.000,2357.05,2361.75,2314.95,2320.0,401896.0,Dr. Lal Pathlabs Q1 Results Review - Lack Of Volume Precludes Constructive Stance: Yes Securities,Revenues came in line with 7.6% YoY growth (9.7% non-Covid growth); sample growth of 6% but little by way of volumes.,neutral,positive,-1.5718801043677555,negative,0.906376855173022,positive
2023-07-31 15:33:33.000,2327.95,2368.0,2327.4,2349.05,221403.0,"Moneycontrol Pro Panorama | Even in a weakened state, China’s overhang over metals to continue","In today’s edition of Moneycontrol Pro Panorama: India’s drug regulation process needs overhaul, price hikes effect Dr Lal PathLabs’ performance, no push to the climate agenda at G20 summit, and more",negative,neutral,0.906376855173022,positive,-2.1938232161874334,negative
2023-08-09 11:30:01.000,2379.4,2393.2,2355.0,2380.95,115599.0,“Dr Lal PathLabs Ltd’s Share Price Rises 0.68% After 43.6% Increase in Profit for Q2 2023”,"Dr Lal PathLabs Ltd’s share price rose 0.68% after it reported 43.6% increase in profit for Q1 FY24. Revenues were up 7.76% to ₹541 crore. EBITDA rose 24.4% YoY to ₹146 crore. Intense competition in Delhi NCR may limit earnings growth. Stock downgraded to sell with revised target price of ₹2,110.",neutral,positive,0.0651424728923143,neutral,-0.5637049455154995,neutral
